News &
Publications

Katherine Kayser-Bricker, Chief Scientific Officer of Halda Therapeutics Recognized in Endpoints News’ Women in BioPharma R&D Special Report

New Haven, CT – October 7, 2025 — Halda Therapeutics, a clinical-stage biotechnology company developing RIPTAC™ therapeutics, novel small molecule therapies, today announced that its Chief Scientific Officer, Katherine Kayser-Bricker, has been named to Endpoints News’ Women in BioPharma R&D 2025 Special Report. The annual feature highlights 20 of the industry’s most innovative and inspiring leaders who are shaping the future of drug discovery and development.

“Kat’s leadership, vision, and scientific excellence have been central to the mission of Halda Therapeutics,” said Christian Schade, President and Chief Executive Officer of Halda Therapeutics. “She exemplifies the very best of biopharma, combining deep scientific rigor with a relentless drive to translate discoveries into new medicines for patients in need. We are thrilled to see her recognized among this year’s honorees.”

Kayser-Bricker has made significant contributions to the biopharmaceutical field and has been instrumental in advancing Halda’s progression of RIPTAC therapeutics. These first-in-class therapies are aimed to address urgent unmet medical needs, Halda’s first clinical program in metastatic castration-resistant prostate cancer (mCRPC)was invented and advanced to clinical development under her scientific leadership.

The Women in BioPharma R&D list, now in its 7th year, has recognized more than 100 leaders since its inception. Selected by the Endpoints News editorial team, the honorees represent a diverse group of scientists, executives, and trailblazers who are redefining what’s possible in the industry.

For more information about the 2025 honorees, please visit https://endpoints.news/special-report-2025-meet-20-women-reshaping-the-future-of-biopharma/.

About Halda Therapeutics
Halda Therapeutics is a clinical-stage biotechnology company that has developed a proprietary RIPTAC™ (Regulated Induced Proximity Targeting Chimeras) modality that works by a novel “hold and kill” mechanism for the precision treatment of cancer and other diseases. The novel mechanism of action of RIPTAC therapeutics is uniquely designed to address cancer’s ability to evolve bypass mechanisms of resistance, a common limitation of today’s precision oncology medicines. Our lead RIPTAC programs are in clinical and pre-clinical development for major solid tumor types with additional RIPTAC therapeutic programs in our pipeline to treat serious disease. Halda is led by a leadership team with deep expertise in biotechnology, drug discovery, platform innovation, and clinical development, and is located in New Haven, CT. For more information, please visit www.haldatx.com and follow us on LinkedIn.

Media Contact:
Kathryn Morris
The Yates Network LLC
914-204-6412
kathryn@theyatesnetwork.com